nor-NOHA monoacetate (Nω-Hydroxy-nor-L-arginine monoacetate) | Arginase Inhibitor | MedChemExpress (2025)

nor-NOHA monoacetate (0.1-1 mM, 72 h) induces apoptosis in a dose-dependent manner under hypoxia (1.5% O₂) in K562 cells^[1].
nor-NOHA monoacetate (1 mM, 72 h) attenuates hypoxia-mediated resistance towards imatinib in K562 or KCL22 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

nor-NOHA monoacetate (100 mg/kg, i.v., once time) induces a significant reduction of infarct size in male Sprague-Dawley rats^[2].
nor-NOHA monoacetate (100 mg/kg, i.v., once time) increases plasma citrulline and nitrite levels and decreases the ornithine plasma levels in male Sprague-Dawley rats^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2250019-93-1

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

DMSO : 100 mg/mL (423.32 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 50 mg/mL (211.66 mM; Need ultrasonic)

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

• Protocol 1

  Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

  Solubility: ≥ 2.5 mg/mL (10.58 mM); Clear solution

  This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

  Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

  Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

• Protocol 2

  Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

  Solubility: ≥ 2.5 mg/mL (10.58 mM); Clear solution

  This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

  Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

  Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

• Protocol 1

  Add each solvent one by one: PBS

  Solubility: 100 mg/mL (423.32 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

• [1]. Ng KP, et al. The arginase inhibitor Nω-hydroxy-nor-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target. PLoS One. 2018 Oct 11;13(10):e0205254. [Content Brief]

  [2]. Jung C, et al. Arginase inhibition mediates cardioprotection during ischaemia-reperfusion. Cardiovasc Res. 2010 Jan 1;85(1):147-54. [Content Brief]